Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks clues to predict transplant complication

NCT ID NCT04188912

Knowledge-focused Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 267 adults who had stem cell transplants to understand why some develop chronic graft-versus-host disease (GVHD), a common complication. Researchers collected blood, saliva, tears, and tissue samples, along with eye scans and breathing tests, to find early signs of the condition. The goal is to help doctors predict and detect chronic GVHD sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict and catch chronic GVHD earlier after stem cell transplants.
What could go wrong
This is an observational study, not testing a treatment. It may not lead to direct improvements for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

267 people

The number who actually took part.

Started

Sep 2019

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for allogeneic hematopoietic cell transplantation (HCT) from any donor for any indication, with a risk of cGVHD of \> 25%

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults age 18 or older * Scheduled for allogeneic HCT from any donor for any indication, with a risk of cGVHD of \> 25% (see below in exclusion criteria for treatment plans with a cGVHD risk \< 25%) * Ability and willingness to comply with the intensive assessment schedule including evaluation every other month at a participating site * Ability to communicate in English or Spanish, to allow completion of patient surveys and clear communication with the study team Exclusion Criteria: * Receipt of umbilical cord blood, bone marrow with post-transplant cyclophosphamide (peripheral blood with post-transplant cyclophosphamide is allowed), anti-thymocyte globulin, alemtuzumab, or ex-vivo T-cell depletion. These patients are excluded because they have a cGVHD risk of \< 25% * Hematologic malignancy with active disease at the time of transplant. Minimal residual disease is allowed * Hematopoietic cell transplant co-morbidity index \> 4 based on parameters known at time of enrollment * Prior allogeneic transplant * Prior autoimmune disease with ongoing symptoms * History of noncompliance * Inability to comply with study requirements due to geographic, logistic, social or any other factors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphoid cell neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic and lymphoid cell neoplasm

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • National Cancer Institute

    Bethesda, Maryland, 20892, United States

  • Roswell Park

    Buffalo, New York, 14263, United States

  • University of Florida

    Gainesville, Florida, 32610, United States

  • Vanderbilt

    Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.